市場調査レポート
商品コード
1172631

ヘルペス治療の世界市場 2023-2027

Global Herpes Treatment Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
ヘルペス治療の世界市場 2023-2027
出版日: 2022年11月30日
発行: TechNavio
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートではヘルペス治療の市場規模は、2023年から2027年の間に9億2,028万米ドルの増加が見込まれ、予測期間中に3.76%のCAGRで成長する見込みであるとしています。当レポートでは、ヘルペス治療市場の全体分析、市場規模・予測、動向、成長促進要因・課題、約25のベンダーを網羅したベンダー分析などをお届けします。

現在の世界の市場動向と促進要因、市場全体の環境に関する最新の分析を提供しています。

市場は、ヘルペス感染症の有病率の増加、患者数の多さ、高齢者層における帯状疱疹の有病率の上昇によって牽引されています。

本調査では、今後数年間におけるヘルペス治療市場の成長を牽引する主要な理由の一つとして、新規治療法の出現を挙げています。また、ワクチン開発への注力やヘルペスの安全な治療法の開発に関する研究の増加が、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界のヘルペス治療市場2017~2021年
  • 製品セグメント分析2017-2021
  • タイプセグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 製品別の市場セグメンテーション

  • 市場内訳
  • 製品別比較
  • ワクチン接種 - 市場規模と予測 2022-2027
  • 薬物療法 - 市場規模と予測 2022-2027
  • 製品別の市場機会

第7章 タイプ別の市場セグメンテーション

  • 市場内訳
  • タイプ別比較
  • 帯状疱疹 - 市場規模と予測 2022-2027
  • 単純ヘルペス - 市場規模と予測 2022-2027
  • タイプ別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • 日本 - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • フランス - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • 地域情勢別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • AiCuris Anti infective Cures AG
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • Fresenius SE and Co. KGaA
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Maruho Co. Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global herpes treatment market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Product - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Product - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Product
  • Exhibits33: Data Table on Comparison by Product
  • Exhibits34: Chart on Vaccination - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Vaccination - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Vaccination - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Vaccination - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Drug therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Drug therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Drug therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Drug therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Product ($ million)
  • Exhibits43: Chart on Type - Market share 2022-2027 (%)
  • Exhibits44: Data Table on Type - Market share 2022-2027 (%)
  • Exhibits45: Chart on Comparison by Type
  • Exhibits46: Data Table on Comparison by Type
  • Exhibits47: Chart on Herpes zoster - Market size and forecast 2022-2027 ($ million)
  • Exhibits48: Data Table on Herpes zoster - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Chart on Herpes zoster - Year-over-year growth 2022-2027 (%)
  • Exhibits50: Data Table on Herpes zoster - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Chart on Herpes simplex - Market size and forecast 2022-2027 ($ million)
  • Exhibits52: Data Table on Herpes simplex - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Chart on Herpes simplex - Year-over-year growth 2022-2027 (%)
  • Exhibits54: Data Table on Herpes simplex - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Market opportunity by Type ($ million)
  • Exhibits56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits57: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits59: Chart on Geographic comparison
  • Exhibits60: Data Table on Geographic comparison
  • Exhibits61: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits63: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits64: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits67: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits71: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits77: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits78: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits79: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits80: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits81: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits82: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits83: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits84: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits87: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits89: Chart on France - Market size and forecast 2022-2027 ($ million)
  • Exhibits90: Data Table on France - Market size and forecast 2022-2027 ($ million)
  • Exhibits91: Chart on France - Year-over-year growth 2022-2027 (%)
  • Exhibits92: Data Table on France - Year-over-year growth 2022-2027 (%)
  • Exhibits93: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits95: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits96: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits97: Market opportunity By Geographical Landscape ($ million)
  • Exhibits98: Impact of drivers and challenges in 2022 and 2027
  • Exhibits99: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits100: Overview on factors of disruption
  • Exhibits101: Impact of key risks on business
  • Exhibits102: Vendors covered
  • Exhibits103: Matrix on vendor position and classification
  • Exhibits104: AbbVie Inc. - Overview
  • Exhibits105: AbbVie Inc. - Product / Service
  • Exhibits106: AbbVie Inc. - Key news
  • Exhibits107: AbbVie Inc. - Key offerings
  • Exhibits108: AiCuris Anti infective Cures AG - Overview
  • Exhibits109: AiCuris Anti infective Cures AG - Product / Service
  • Exhibits110: AiCuris Anti infective Cures AG - Key offerings
  • Exhibits111: Aurobindo Pharma Ltd. - Overview
  • Exhibits112: Aurobindo Pharma Ltd. - Product / Service
  • Exhibits113: Aurobindo Pharma Ltd. - Key offerings
  • Exhibits114: Cadila Healthcare Ltd. - Overview
  • Exhibits115: Cadila Healthcare Ltd. - Business segments
  • Exhibits116: Cadila Healthcare Ltd. - Key news
  • Exhibits117: Cadila Healthcare Ltd. - Key offerings
  • Exhibits118: Cadila Healthcare Ltd. - Segment focus
  • Exhibits119: Cipla Ltd. - Overview
  • Exhibits120: Cipla Ltd. - Business segments
  • Exhibits121: Cipla Ltd. - Key news
  • Exhibits122: Cipla Ltd. - Key offerings
  • Exhibits123: Cipla Ltd. - Segment focus
  • Exhibits124: Eli Lilly and Co. - Overview
  • Exhibits125: Eli Lilly and Co. - Product / Service
  • Exhibits126: Eli Lilly and Co. - Key offerings
  • Exhibits127: Fresenius SE and Co. KGaA - Overview
  • Exhibits128: Fresenius SE and Co. KGaA - Business segments
  • Exhibits129: Fresenius SE and Co. KGaA - Key news
  • Exhibits130: Fresenius SE and Co. KGaA - Key offerings
  • Exhibits131: Fresenius SE and Co. KGaA - Segment focus
  • Exhibits132: Gilead Sciences Inc. - Overview
  • Exhibits133: Gilead Sciences Inc. - Product / Service
  • Exhibits134: Gilead Sciences Inc. - Key news
  • Exhibits135: Gilead Sciences Inc. - Key offerings
  • Exhibits136: GlaxoSmithKline Plc - Overview
  • Exhibits137: GlaxoSmithKline Plc - Business segments
  • Exhibits138: GlaxoSmithKline Plc - Key offerings
  • Exhibits139: GlaxoSmithKline Plc - Segment focus
  • Exhibits140: Maruho Co. Ltd. - Overview
  • Exhibits141: Maruho Co. Ltd. - Product / Service
  • Exhibits142: Maruho Co. Ltd. - Key offerings
  • Exhibits143: Merck and Co. Inc. - Overview
  • Exhibits144: Merck and Co. Inc. - Business segments
  • Exhibits145: Merck and Co. Inc. - Key news
  • Exhibits146: Merck and Co. Inc. - Key offerings
  • Exhibits147: Merck and Co. Inc. - Segment focus
  • Exhibits148: Novartis AG - Overview
  • Exhibits149: Novartis AG - Business segments
  • Exhibits150: Novartis AG - Key offerings
  • Exhibits151: Novartis AG - Segment focus
  • Exhibits152: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibits153: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibits154: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits155: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits156: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits157: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits158: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits159: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits160: Viatris Inc. - Overview
  • Exhibits161: Viatris Inc. - Business segments
  • Exhibits162: Viatris Inc. - Key offerings
  • Exhibits163: Viatris Inc. - Segment focus
  • Exhibits164: Inclusions checklist
  • Exhibits165: Exclusions checklist
  • Exhibits166: Currency conversion rates for US$
  • Exhibits167: Research methodology
  • Exhibits168: Validation techniques employed for market sizing
  • Exhibits169: Information sources
  • Exhibits170: List of abbreviations
目次
Product Code: IRTNTR44343

Technavio has been monitoring the herpes treatment market and it is poised to grow by $920.28 mn during 2023-2027, decelerating at a CAGR of 3.76% during the forecast period. Our report on the herpes treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of herpes infection, the large patient pool, and the rising prevalence rate of shingles in older population.

Technavio's herpes treatment market is segmented as below:

By Product

  • Vaccination
  • Drug therapy

By Type

  • Herpes zoster
  • Herpes simplex

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the emergence of novel therapies as one of the prime reasons driving the herpes treatment market growth during the next few years. Also, increasing focus on vaccine development and increasing research on developing a safe treatment for herpes will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the herpes treatment market covers the following areas:

  • Herpes treatment market sizing
  • Herpes treatment market forecast
  • Herpes treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading herpes treatment market vendors that include AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Cadila Healthcare Ltd., CENTURION REMEDIES Pvt. Ltd., Cipla Ltd., Eli Lilly and Co., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Bausch Health Co Inc. Also, the herpes treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global herpes treatment market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global herpes treatment market 2017 - 2021 ($ million)
  • 4.2 Product Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.3 Type Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

  • 6.1 Market segments
  • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
  • 6.2 Comparison by Product
  • Exhibit 32: Chart on Comparison by Product
  • Exhibit 33: Data Table on Comparison by Product
  • 6.3 Vaccination - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Vaccination - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Vaccination - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Vaccination - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Vaccination - Year-over-year growth 2022-2027 (%)
  • 6.4 Drug therapy - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Drug therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Drug therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Drug therapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Drug therapy - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product
  • Exhibit 42: Market opportunity by Product ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
  • Exhibit 43: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 44: Data Table on Type - Market share 2022-2027 (%)
  • 7.2 Comparison by Type
  • Exhibit 45: Chart on Comparison by Type
  • Exhibit 46: Data Table on Comparison by Type
  • 7.3 Herpes zoster - Market size and forecast 2022-2027
  • Exhibit 47: Chart on Herpes zoster - Market size and forecast 2022-2027 ($ million)
  • Exhibit 48: Data Table on Herpes zoster - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Chart on Herpes zoster - Year-over-year growth 2022-2027 (%)
  • Exhibit 50: Data Table on Herpes zoster - Year-over-year growth 2022-2027 (%)
  • 7.4 Herpes simplex - Market size and forecast 2022-2027
  • Exhibit 51: Chart on Herpes simplex - Market size and forecast 2022-2027 ($ million)
  • Exhibit 52: Data Table on Herpes simplex - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Chart on Herpes simplex - Year-over-year growth 2022-2027 (%)
  • Exhibit 54: Data Table on Herpes simplex - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Type
  • Exhibit 55: Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 57: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 59: Chart on Geographic comparison
  • Exhibit 60: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Japan - Market size and forecast 2022-2027
  • Exhibit 81: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 82: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 83: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibit 84: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • 9.9 Germany - Market size and forecast 2022-2027
  • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.10 France - Market size and forecast 2022-2027
  • Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ million)
  • Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ million)
  • Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%)
  • Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%)
  • 9.11 UK - Market size and forecast 2022-2027
  • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 97: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 98: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 100: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 101: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 102: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 103: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 104: AbbVie Inc. - Overview
  • Exhibit 105: AbbVie Inc. - Product / Service
  • Exhibit 106: AbbVie Inc. - Key news
  • Exhibit 107: AbbVie Inc. - Key offerings
  • 12.4 AiCuris Anti infective Cures AG
  • Exhibit 108: AiCuris Anti infective Cures AG - Overview
  • Exhibit 109: AiCuris Anti infective Cures AG - Product / Service
  • Exhibit 110: AiCuris Anti infective Cures AG - Key offerings
  • 12.5 Aurobindo Pharma Ltd.
  • Exhibit 111: Aurobindo Pharma Ltd. - Overview
  • Exhibit 112: Aurobindo Pharma Ltd. - Product / Service
  • Exhibit 113: Aurobindo Pharma Ltd. - Key offerings
  • 12.6 Cadila Healthcare Ltd.
  • Exhibit 114: Cadila Healthcare Ltd. - Overview
  • Exhibit 115: Cadila Healthcare Ltd. - Business segments
  • Exhibit 116: Cadila Healthcare Ltd. - Key news
  • Exhibit 117: Cadila Healthcare Ltd. - Key offerings
  • Exhibit 118: Cadila Healthcare Ltd. - Segment focus
  • 12.7 Cipla Ltd.
  • Exhibit 119: Cipla Ltd. - Overview
  • Exhibit 120: Cipla Ltd. - Business segments
  • Exhibit 121: Cipla Ltd. - Key news
  • Exhibit 122: Cipla Ltd. - Key offerings
  • Exhibit 123: Cipla Ltd. - Segment focus
  • 12.8 Eli Lilly and Co.
  • Exhibit 124: Eli Lilly and Co. - Overview
  • Exhibit 125: Eli Lilly and Co. - Product / Service
  • Exhibit 126: Eli Lilly and Co. - Key offerings
  • 12.9 Fresenius SE and Co. KGaA
  • Exhibit 127: Fresenius SE and Co. KGaA - Overview
  • Exhibit 128: Fresenius SE and Co. KGaA - Business segments
  • Exhibit 129: Fresenius SE and Co. KGaA - Key news
  • Exhibit 130: Fresenius SE and Co. KGaA - Key offerings
  • Exhibit 131: Fresenius SE and Co. KGaA - Segment focus
  • 12.10 Gilead Sciences Inc.
  • Exhibit 132: Gilead Sciences Inc. - Overview
  • Exhibit 133: Gilead Sciences Inc. - Product / Service
  • Exhibit 134: Gilead Sciences Inc. - Key news
  • Exhibit 135: Gilead Sciences Inc. - Key offerings
  • 12.11 GlaxoSmithKline Plc
  • Exhibit 136: GlaxoSmithKline Plc - Overview
  • Exhibit 137: GlaxoSmithKline Plc - Business segments
  • Exhibit 138: GlaxoSmithKline Plc - Key offerings
  • Exhibit 139: GlaxoSmithKline Plc - Segment focus
  • 12.12 Maruho Co. Ltd.
  • Exhibit 140: Maruho Co. Ltd. - Overview
  • Exhibit 141: Maruho Co. Ltd. - Product / Service
  • Exhibit 142: Maruho Co. Ltd. - Key offerings
  • 12.13 Merck and Co. Inc.
  • Exhibit 143: Merck and Co. Inc. - Overview
  • Exhibit 144: Merck and Co. Inc. - Business segments
  • Exhibit 145: Merck and Co. Inc. - Key news
  • Exhibit 146: Merck and Co. Inc. - Key offerings
  • Exhibit 147: Merck and Co. Inc. - Segment focus
  • 12.14 Novartis AG
  • Exhibit 148: Novartis AG - Overview
  • Exhibit 149: Novartis AG - Business segments
  • Exhibit 150: Novartis AG - Key offerings
  • Exhibit 151: Novartis AG - Segment focus
  • 12.15 Sun Pharmaceutical Industries Ltd.
  • Exhibit 152: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibit 153: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibit 154: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 12.16 Teva Pharmaceutical Industries Ltd.
  • Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.17 Viatris Inc.
  • Exhibit 160: Viatris Inc. - Overview
  • Exhibit 161: Viatris Inc. - Business segments
  • Exhibit 162: Viatris Inc. - Key offerings
  • Exhibit 163: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 164: Inclusions checklist
  • Exhibit 165: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 166: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 167: Research methodology
  • Exhibit 168: Validation techniques employed for market sizing
  • Exhibit 169: Information sources
  • 13.5 List of abbreviations
  • Exhibit 170: List of abbreviations